🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationLyophilization process for peptides — need advice

Lyophilization process for peptides — need advice

kim_atl_prep Mon, Jun 23, 2025 at 5:05 PM 15 replies 1,430 viewsPage 1 of 3
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Jun 23, 2025 at 5:05 PM#1

Writing this once so I can stop repeating it across threads. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

The condition it depends on

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

What would genuinely help is knowing what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. I would rather have one careful answer than five confident ones.

— kim_atl_prep · corrections welcome and will be edited into this post with credit
41 19PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 38 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Jun 23, 2025 at 5:22 PM#2
kim_atl_prep said:
They are two different exemptions from the same federal requirements and they buy different things.

Agreeing with kim_atl_prep, and the qualification matters more than the agreement. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

42 20RunnerRach, TrialNerd_Beth, HPLC_Greg and 39 others
Reply Quote Save Share Report
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Jun 23, 2025 at 5:39 PM#3
kim_atl_prep said:
They are two different exemptions from the same federal requirements and they buy different things.

I read this differently from kim_atl_prep, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

43 21josh_phd_bmore, roxy_nash, tony_orlando and 40 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Jun 23, 2025 at 5:56 PM#4

Short answer first, then the reasoning. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: Jun 23, 2025 at 10:56 PM
44 22Dr.SurgeonPGH, rachel_ABQ, traveltech_sara and 41 others
Reply Quote Save Share Report
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
Jun 23, 2025 at 7:25 PM#5
pete_manc_UK said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

This matches mine closely enough to be worth saying so out loud. Posting only so the count is not one.

45 23lisa_labSD, adam_van, Dr.SurgeonPGH and 42 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register